| 51.26 Real-Time Quote |  +0.46 / +0.91%Today’s Change | 40.31 Today|||52-Week Range 53.45 | +8.44% Year-to-Date |
| Priority Review for AZN/BMY Drug - Analyst Blog 12:03pm / Zacks.com | NICE News for BMY/AstraZeneca - Analyst Blog May 30 / Zacks.com |
| Encouraging Data on Isis Candidate - Analyst Blog 11:16am / Zacks.com | AstraZeneca to Buy Omthera Pharma - Analyst Blog May 29 / Zacks.com |
| AstraZeneca to Return Fostamatinib Rights - Analyst Blog Jun 05 / Zacks.com | AZN Updates on Pulmicort Respules - Analyst Blog May 28 / Zacks.com |
| How AstraZeneca Measures Up as a GARP Investment Jun 05 / MotleyFool.com | Impax Launches Generic Zomig - Analyst Blog May 23 / Zacks.com |
| AstraZeneca Presents Olaparib Data - Analyst Blog Jun 03 / Zacks.com | Data on AstraZeneca's Naloxegol - Analyst Blog May 23 / Zacks.com |
| Previous close | 50.80 |
| Today’s open | 51.18 |
| Day’s range | 51.01 - 51.41 |
| Volume | 1,452,531 |
| Average volume (3 months) | 2,034,393 |
| Market cap | $63.6B |
| Dividend yield | 5.47% |
| Earnings growth (last year) | -32.08% |
| Earnings growth (this year) | -- |
| Earnings growth (next 5 years) | -7.55% |
| Revenue growth (last year) | -16.81% |
| P/E ratio | 16.1 |
| Price/Sales | 2.13 |
| Price/Book | 2.67 |
| Today’s change | Today’s % change | |
|---|---|---|
| ABBVAbbVie Inc | +0.14 | +0.33% |
| LLYEli Lilly and Co | +0.05 | +0.11% |
| NVONovo Nordisk A/S | +0.57 | +0.35% |
| ABTAbbott Laboratories | +0.30 | +0.83% |
| Next reporting date | August 1, 2013 |
| EPS forecast (this quarter) | $1.16 |
| Annual revenue (last year) | $28.0B |
| Annual profit (last year) | $6.3B |
| Net profit margin | 22.51% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
Chief Executive Officer & Executive Director Pascal Soriot, PhD, MBA |
EVP-Global Operations & Information Services David Smith |
Corporate headquarters London, London & South East |
.
